How Tagrisso Targets Lung Cancer Mutations
Tagrisso (osimertinib) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved for non-small cell lung cancer (NSCLC) with specific EGFR mutations. It binds irreversibly to mutated EGFR proteins on cancer cells, blocking their signaling pathway that drives uncontrolled cell growth.[1]
Which Mutations Does Tagrisso Treat?
Tagrisso primarily targets:
- EGFR exon 19 deletions (most common sensitizing mutation, ~45% of EGFR-mutant NSCLC cases).
- EGFR L858R point mutation (~40-45% of cases).
- T790M resistance mutation (arises in ~50-60% of patients after first- or second-generation TKIs like gefitinib or erlotinib fail).
It received FDA approval in 2015 for T790M-positive metastatic NSCLC after progression on prior EGFR therapy, expanded in 2018 as first-line treatment for exon 19 deletion or L858R mutations, and further for adjuvant use post-resection in 2021.[1][2]
Mechanism of Action Step-by-Step
1. EGFR Overactivation: In EGFR-mutant NSCLC, mutations cause the EGFR receptor on lung cell surfaces to stay "on," constantly signaling through pathways like RAS-RAF-MEK-ERK and PI3K-AKT to promote tumor proliferation, survival, and metastasis.
2. Selective Binding: Tagrisso enters cancer cells and covalently binds to a cysteine residue (C797) in the EGFR kinase domain, especially in mutants. This irreversible binding locks the kinase in an inactive state, preventing ATP from fueling phosphorylation.
3. Sparks Cancer Cell Death: Blocked signaling halts DNA replication and triggers apoptosis. Tagrisso penetrates the blood-brain barrier effectively, targeting CNS metastases common in EGFR-mutant NSCLC (up to 30-40% of cases).[1][3]
Unlike earlier TKIs, Tagrisso avoids wild-type EGFR inhibition at therapeutic doses, reducing skin rash and diarrhea side effects.
How It Handles Resistance
T790M mutation sterically hinders reversible TKIs. Tagrisso's design exploits this by fitting precisely into the mutant pocket. However, new resistances emerge, like C797S (blocks covalent binding) or MET amplifications, often after 10-18 months. Combination therapies (e.g., with chemotherapy or amivantamab) address these.[2][4]
Common Side Effects Patients Experience
Diarrhea (58%), rash (58%), dry skin (36%), nail changes (35%), and interstitial lung disease (rare but serious, ~4%). Interruption or dose reduction manages most; monitor liver function and QT interval.[1]
Who Makes Tagrisso and Upcoming Competition?
AstraZeneca manufactures Tagrisso, a blockbuster generating $5.8 billion in 2023 sales. Patents protect it until ~2032 in the US (with pediatric exclusivity to 2033); challenges from generics like MSN Laboratories are ongoing. No biosimilars yet, but first-line alternatives include lazertinib (U.S. approval 2024) and amivantamab.[5] Check DrugPatentWatch.com for exact expiry dates and litigation.
Sources
[1]: FDA Label for Tagrisso
[2]: NEJM: FLAURA Trial (2018)
[3]: Nature Reviews Cancer: EGFR TKIs (2020)
[4]: JCO: Resistance Mechanisms (2021)
[5]: DrugPatentWatch.com - Tagrisso